Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference
November 09, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
Fireside Chat Webcast on Tuesday, November 14, 2017 at 8:45 a.m. Eastern Time ANN ARBOR, Mich., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results
November 07, 2017 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill
November 06, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
– Top-Line Results Expected by the Fourth Quarter of 2018 – – NDA Submission for LDL-C Lowering Indication for the Bempedoic Acid / Ezetimibe Combination Pill Expected by First Quarter 2019 – ANN...
Esperion to Host Analyst and Investor Day Event on October 17
October 10, 2017 08:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results
August 08, 2017 08:00 ET
|
Esperion Therapeutics, Inc.
– Phase 3 Enrollment Progress Supports NDA Submissions for LDL-C Lowering Indications for Bempedoic Acid / Ezetimibe Combination Pill and Bempedoic Acid by the First Quarter 2019 –– Conference Call...
Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin
August 08, 2017 07:30 ET
|
Esperion Therapeutics, Inc.
– 1002-038 Study Meets Primary Endpoint With a Robust 64% LDL-C Lowering Efficacy –– Clinically Relevant 48% hsCRP Reduction –– The Combination Therapy Was Observed to be Safe and Well-Tolerated ––...